An Observational, Prospective Cohort Study, on Blood Coagulation Parameters in Postmenopausal Patients With Operable Breast Cancer Who Are Treated as Per Standard Practice With Adjuvant Hormonal Therapy for a Total of 5 Years
Study subjects will be treated with standard adjuvant hormonal therapy for a total of 5
years or until disease relapse or until HT is permanently discontinued for other reasons.
The choice of endocrine treatment strategy (drugs to be used or their sequence, if the
sequential option has been decided) is left at the discretion of the participating site.
Adjuvant HT will commence after the completion of adjuvant chemotherapy and/or radiotherapy.
Percentage change (%) from baseline of the blood coagulation parameters at 6, 12, 18, and 24
months of treatment. The blood coagulation parameters which will be measured are fibrinogen,
prothrombin time (PT) and activated partial thromboplastin time (aPTT).
Observational Model: Cohort, Time Perspective: Prospective
Percentage change (%) from baseline of the blood coagulation parameters (fibrinogen, PT, aPTT) at 6, 12, 18, and 24 months of treatment.
Christos Markopoulos, MD
Hellenic Breast Surgeons Society
Greece: National Organization of Medicines